Through this novel venture fund, the American Heart Association and its co-investors will work closely together to identify and fund best-in-class healthcare technology companies with scalable products and services. Entrepreneurs and emerging companies who are interested in submitting their innovative products and solutions to improve the quality of healthcare delivery can submit directly to Aphelion Capital.
“Cardiovascular disease costs are projected to exceed USD 1 trillion by 2035,” said Nancy Brown, CEO of the American Heart Association. “New approaches are urgently needed to increase prevention and treatment strategies to reverse the trend for those already suffering from heart diseases, as well as prevent populations from ever getting heart disease. Through Cardeation Capital, we expect to deliver better outcomes and improve the quality of healthcare delivery for the people who are counting on us the most.”
“At Philips our goal is to improve the lives of 3 billion people a year by 2025. To achieve this ambition, we co-create solutions with healthcare providers, invest in start-ups, and partner with other industry players,” said Rich Wilmot, head of Health Technology Ventures, Philips. “Together with the American Heart Association and UPMC, through the Cardeation Capital venture capital fund we will invest in innovative healthcare products, services and solutions that have the potential to improve the lives of cardiovascular disease and stroke patients.”
“As one of the largest integrated health systems in the United States, UPMC is making significant investments in the disruptive technologies needed to dramatically improve the quality and effectiveness of healthcare,” said Tal Heppenstall, president of UPMC Enterprises, the commercialization arm of UPMC. “We expect that Cardeation Capital, working closely with our world-renowned clinicians at UPMC Heart and Vascular Institute, will play a critical role in this strategy for the benefit of our patients.”
“Our organization is committed to investing in low capital-intensive entrepreneurial opportunities that will improve healthcare quality while reducing costs in our healthcare system,” said Ned Scheetz, founder and managing partner of Aphelion Capital. “Through Cardeation Capital, we aim to strategically invest in a collaborative manner that will leverage the collective knowledge and experience of these top in field global organizations. We look forward to working closely with our partners to address today’s real-world issues associated with healthcare delivery.”
Visit www.aphelioncapital.net for more information.